AbbVie Inc. (NYSE:ABBV) – Analysts at Leerink Swann issued their Q1 2018 EPS estimates for AbbVie in a report released on Tuesday. Leerink Swann analyst G. Porges expects that the company will post earnings of $1.56 per share for the quarter. Leerink Swann has a “Buy” rating and a $106.00 price objective on the stock. Leerink Swann also issued estimates for AbbVie’s Q4 2018 earnings at $1.89 EPS.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.21 EPS.

A number of other analysts have also recently weighed in on ABBV. Evercore ISI initiated coverage on shares of AbbVie in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $95.00 target price on the stock. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 6th. Jefferies Group reissued a “buy” rating and issued a $94.00 target price on shares of AbbVie in a research note on Friday, September 8th. Goldman Sachs Group reissued a “buy” rating and issued a $100.00 target price (up previously from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Finally, Cowen reissued a “hold” rating and issued a $95.00 target price (up previously from $70.00) on shares of AbbVie in a research note on Monday, September 11th. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $96.66.

AbbVie (ABBV) traded down $1.01 during midday trading on Wednesday, reaching $94.40. 5,114,200 shares of the company were exchanged, compared to its average volume of 6,120,710. The company has a market capitalization of $152,315.39, a PE ratio of 17.97, a P/E/G ratio of 1.35 and a beta of 1.52. AbbVie has a twelve month low of $58.80 and a twelve month high of $98.52. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45.

Several hedge funds have recently made changes to their positions in the company. Formidable Asset Management LLC lifted its position in shares of AbbVie by 0.3% during the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock worth $285,000 after purchasing an additional 10 shares in the last quarter. WealthTrust Axiom LLC lifted its position in shares of AbbVie by 0.3% during the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock worth $312,000 after purchasing an additional 15 shares in the last quarter. Abner Herrman & Brock LLC lifted its position in shares of AbbVie by 0.3% during the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after purchasing an additional 18 shares in the last quarter. Bollard Group LLC lifted its position in shares of AbbVie by 0.5% during the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after purchasing an additional 19 shares in the last quarter. Finally, St. Louis Trust Co lifted its position in shares of AbbVie by 0.7% during the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock worth $248,000 after purchasing an additional 23 shares in the last quarter. Institutional investors own 69.32% of the company’s stock.

In other AbbVie news, Chairman Richard A. Gonzalez sold 218,193 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now directly owns 492,030 shares in the company, valued at $46,255,740.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael Severino sold 25,633 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the transaction, the executive vice president now owns 114,922 shares in the company, valued at $10,881,964.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 277,125 shares of company stock worth $25,891,756. Company insiders own 0.23% of the company’s stock.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a $0.71 dividend. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a yield of 3.01%. AbbVie’s payout ratio is 62.29%.

ILLEGAL ACTIVITY NOTICE: “Leerink Swann Weighs in on AbbVie Inc.’s Q1 2018 Earnings (ABBV)” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/07/leerink-swann-weighs-in-on-abbvie-inc-s-q1-2018-earnings-abbv.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.